Russell B Van Dyke

Summary

Affiliation: Tulane University
Country: USA

Publications

  1. pmc Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis
    Barbara A Rath
    Department of Pediatrics, Division of Pneumonology Immunology, Charite University Medical Center, Berlin, Germany
    BMC Infect Dis 13:1. 2013
  2. pmc A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Infect Dis 54:285-93. 2012
  3. ncbi request reprint Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Pediatrics 109:e61. 2002
  4. doi request reprint Mother-to-child transmission of HIV-1 in the era prior to the availability of combination antiretroviral therapy: the role of drugs of abuse
    Russell B Van Dyke
    Tulane University Health Sciences, New Orleans, LA 70112, United States
    Life Sci 88:922-5. 2011
  5. pmc Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA, USA
    J Acquir Immune Defic Syndr 57:165-73. 2011
  6. pmc Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    J Infect Dis 198:1599-608. 2008
  7. pmc Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment
    Paige L Williams
    aCenter for Biostatistics in AIDS Research bDepartment of Biostatistics, Harvard School of Public Health, Boston, Massachusetts cDepartment of Pediatrics Infectious Diseases, University of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado dTulane University School of Medicine, New Orleans, Louisiana eEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland fDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts gSection of Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana hDepartment of Pediatrics, University of Colorado School of Medicine, Denver, Colorado iNew York University School of Medicine, New York jDepartment of Pediatrics, New Jersey Medical School, Newark, New Jersey kSaban Research Institute, Children s Hospital Los Angeles, Los Angeles, California, USA
    AIDS 27:1959-70. 2013
  8. pmc Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus
    Kunjal Patel
    Department of Epidemiology, Harvard School of Public Health, Boston, MA K P, G R S Center for Biostatistics in AIDS Research, Boston, MA K P, J W, D L J, G R S, P L W Department of Pediatrics, Wayne State University School of Medicine, Children s Hospital of Michigan, Detroit S E L Division of Pediatric Clinical Research and Division of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL D C L, G B S, J D W, T L M Saban Research Institute of Children s Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA M E G Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis L A D M Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA R B V D Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD G K S Department of Pediatrics, Baylor College of Medicine, Texas Children s Hospital, Houston W T S Department of Pediatrics, Northwestern University Feinberg School of Medicine, Children s Memorial Hospital, Chicago, IL L Y Division of Cardiology, University of Maryland School of Medicine, Brazil
    Circulation 129:1204-12. 2014
  9. ncbi request reprint Growth at Two Years of Age in HIV-Exposed Uninfected Children in the US by Trimester of Maternal Antiretroviral Initiation
    Denise L Jacobson
    1 Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston MA, USA 2 Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, USA 3 The Saban Research Institute, Children s Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, USA 4 Maternal and Pediatric Infectious Disease MPID Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, USA 5 Indiana University School of Medicine, Indianapolis, USA 6 University of Alabama School of Medicine, Birmingham, USA 7 University of Florida, Jacksonville, USA 8 Drexel University College of Medicine, Philadelphia, USA 9 Children s Hospital Colorado, Denver, USA 10 Tulane University School of Medicine, New Orleans, USA 11 University of Illinois at Chicago, Chicago, USA 12 New York University Langone Medical Center, New York, USA 13 Division of Pediatric Clinical Research, Department of Pediatrics, Miller School of Medicine at the University of Miami, Miami, USA
    Pediatr Infect Dis J . 2016
  10. pmc Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents
    Paul Krogstad
    aDepartment of Pediatrics Infectious Diseases bDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California cDepartment of Epidemiology, Center for Biostatistics in AIDS Research CBAR, Harvard School of Public Health, Boston, Massachusetts dEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland eUniversity of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado fDepartment of Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey gNew York University School of Medicine hAlbert Einstein College of Medicine, New York City, New York, USA iDepartment of Pediatrics, Federal University of Minas Gerais, Minas Gerais, Brazil jTulane University School of Medicine, New Orleans, Louisiana, USA
    AIDS 29:683-93. 2015

Research Grants

  1. TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT
    Russell Van Dyke; Fiscal Year: 2006
  2. Tulane/LSU HIV/AIDS Clinical Trials Networks Unit
    Russell Van Dyke; Fiscal Year: 2007

Detail Information

Publications32

  1. pmc Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis
    Barbara A Rath
    Department of Pediatrics, Division of Pneumonology Immunology, Charite University Medical Center, Berlin, Germany
    BMC Infect Dis 13:1. 2013
    ..The study was conducted in the first cohort of children gaining access to structured ART in Peru...
  2. pmc A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Clin Infect Dis 54:285-93. 2012
    ..We hypothesized that increasing the duration or potency of the tail would further reduce this risk to <10%, using a sensitive assay to measure resistance...
  3. ncbi request reprint Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Pediatrics 109:e61. 2002
    ..Little is known about the adherence of children to HAART. The objective of this study was to identify correlates of adherence to HAART and the relationship between adherence and study outcomes in a pediatric clinical trial...
  4. doi request reprint Mother-to-child transmission of HIV-1 in the era prior to the availability of combination antiretroviral therapy: the role of drugs of abuse
    Russell B Van Dyke
    Tulane University Health Sciences, New Orleans, LA 70112, United States
    Life Sci 88:922-5. 2011
    ..Reasons for this association may be both behavioral and biological. Drug use is associated with poor adherence to ART and medical care. Opioids enhance infection of macrophages by HIV...
  5. pmc Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA, USA
    J Acquir Immune Defic Syndr 57:165-73. 2011
    ..We sought to describe the disease status of a large cohort of such children and identify predictors of their current CD4 count and HIV viral load (VL)...
  6. pmc Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children
    Russell B Van Dyke
    Department of Pediatrics, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    J Infect Dis 198:1599-608. 2008
    ..Human immunodeficiency virus (HIV) therapy includes a backbone of nucleoside reverse-transcriptase inhibitors (NRTIs). Toxicities associated with NRTIs are not fully defined in children...
  7. pmc Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment
    Paige L Williams
    aCenter for Biostatistics in AIDS Research bDepartment of Biostatistics, Harvard School of Public Health, Boston, Massachusetts cDepartment of Pediatrics Infectious Diseases, University of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado dTulane University School of Medicine, New Orleans, Louisiana eEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland fDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts gSection of Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana hDepartment of Pediatrics, University of Colorado School of Medicine, Denver, Colorado iNew York University School of Medicine, New York jDepartment of Pediatrics, New Jersey Medical School, Newark, New Jersey kSaban Research Institute, Children s Hospital Los Angeles, Los Angeles, California, USA
    AIDS 27:1959-70. 2013
    ..To evaluate associations of perinatal HIV infection, HIV disease severity, and combination antiretroviral treatment with age at pubertal onset...
  8. pmc Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus
    Kunjal Patel
    Department of Epidemiology, Harvard School of Public Health, Boston, MA K P, G R S Center for Biostatistics in AIDS Research, Boston, MA K P, J W, D L J, G R S, P L W Department of Pediatrics, Wayne State University School of Medicine, Children s Hospital of Michigan, Detroit S E L Division of Pediatric Clinical Research and Division of Pediatric Infectious Disease and Immunology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL D C L, G B S, J D W, T L M Saban Research Institute of Children s Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA M E G Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis L A D M Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA R B V D Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD G K S Department of Pediatrics, Baylor College of Medicine, Texas Children s Hospital, Houston W T S Department of Pediatrics, Northwestern University Feinberg School of Medicine, Children s Memorial Hospital, Chicago, IL L Y Division of Cardiology, University of Maryland School of Medicine, Brazil
    Circulation 129:1204-12. 2014
    ....
  9. ncbi request reprint Growth at Two Years of Age in HIV-Exposed Uninfected Children in the US by Trimester of Maternal Antiretroviral Initiation
    Denise L Jacobson
    1 Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston MA, USA 2 Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, USA 3 The Saban Research Institute, Children s Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, USA 4 Maternal and Pediatric Infectious Disease MPID Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, USA 5 Indiana University School of Medicine, Indianapolis, USA 6 University of Alabama School of Medicine, Birmingham, USA 7 University of Florida, Jacksonville, USA 8 Drexel University College of Medicine, Philadelphia, USA 9 Children s Hospital Colorado, Denver, USA 10 Tulane University School of Medicine, New Orleans, USA 11 University of Illinois at Chicago, Chicago, USA 12 New York University Langone Medical Center, New York, USA 13 Division of Pediatric Clinical Research, Department of Pediatrics, Miller School of Medicine at the University of Miami, Miami, USA
    Pediatr Infect Dis J . 2016
    ..Abnormal childhood growth may affect future health. Maternal tenofovir (TFV) use was associated with lower body length and head circumference at one year of age in HIV-exposed uninfected (HEU) US children...
  10. pmc Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents
    Paul Krogstad
    aDepartment of Pediatrics Infectious Diseases bDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California cDepartment of Epidemiology, Center for Biostatistics in AIDS Research CBAR, Harvard School of Public Health, Boston, Massachusetts dEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland eUniversity of Colorado School of Medicine and Children s Hospital Colorado, Aurora, Colorado fDepartment of Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey gNew York University School of Medicine hAlbert Einstein College of Medicine, New York City, New York, USA iDepartment of Pediatrics, Federal University of Minas Gerais, Minas Gerais, Brazil jTulane University School of Medicine, New Orleans, Louisiana, USA
    AIDS 29:683-93. 2015
    ..The frequency, severity and significance of these discordant treatment responses remain unclear...
  11. pmc Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers
    Steven E Lipshultz
    aWayne State University School of Medicine and Children s Hospital of Michigan, Detroit, Michigan bUniversity of Miami Leonard M Miller School of Medicine, Miami, Florida cCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts dUniversity of Illinois at Chicago, Chicago, Illinois eTulane University Health Sciences Center, New Orleans, Louisiana fFrontier Science Technology and Research Foundation, Amherst, New York gNational Heart, Lung, and Blood Institute hEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland iBaylor College of Medicine and Texas Children s Hospital, Houston, Texas jBoston Children s Hospital, Boston, Massachusetts, USA
    AIDS 29:91-100. 2015
    ..We evaluated the potential cardiac effects of in-utero exposures to antiretroviral drugs in HIV-exposed but uninfected (HEU) children...
  12. pmc CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States
    Lee Fairlie
    aWits Reproductive Health and HIV Institute WRHI, University of the Witwatersrand, Johannesburg, South Africa bDepartment of Epidemiology, Center for Biostatistics in AIDS Research CBAR, Harvard School of Public Health, Boston, Massachusetts cTulane University School of Medicine, New Orleans, Louisiana dEunice Kennedy Shriver National Institute of Child Health and Human Development NICHD, National Institutes of Health, Bethesda, Maryland eHarvard MIT Division of Health Sciences and Technology, Boston, Massachusetts fJohns Hopkins University School of Medicine, Baltimore, Maryland gJacobi Medical Center Family Based Services, Albert Einstein College of Medicine, Bronx, New York, USA
    AIDS 29:2109-19. 2015
    ..This study compared 12-month CD4 and viral load outcomes in HIV-infected children and adolescents with virological failure, managed with four treatment switch strategies...
  13. pmc Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection
    Murli U Purswani
    Division of Pediatric Infectious Disease, Department of Pediatrics, Bronx Lebanon Hospital Center, Albert Einstein College of Medicine, Bronx, NY Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA Basic Science Laboratory, Center for Cancer Research, National Cancer Institute, Leidos Biomedical Inc Frederick National Laboratory, Frederick, MD Department of Pediatrics, University of California San Diego UCSD, La Jolla, CA Rady Children s Hospital, San Diego, CA Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
    J Acquir Immune Defic Syndr 73:63-8. 2016
    ..2 to 10.0]. We report an unadjusted incidence of 1.2 CKD cases/100 person-years (95% CI: 0.5 to 2.5) in PHIV youth carrying APOL1 high-risk genotypes, with important implications for sub-Saharan Africa. ..
  14. pmc Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study
    Steven E Lipshultz
    Department of Pediatrics, Universityof Miami Leonard M Miller School of Medicine, FL, USA
    JAMA Pediatr 167:520-7. 2013
    ..This study suggests that highly active ART (HAART) does not appear to impair heart function...
  15. pmc Insulin resistance in HIV-infected youth is associated with decreased mitochondrial respiration
    Jody K Takemoto
    aDepartment of Pharmaceutical Sciences, Ben and Maytee Fisch College of Pharmacy, The University of Texas at Tyler, Tyler, Texas bDepartment of Pediatrics, University of Miami, Miller School of Medicine, Miami, Florida cCenter for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, Massachusetts dThe Saban Research Institute of Children s Hospital Los Angeles, Los Angeles, California eTulane University School of Medicine, New Orleans, Louisiana fDepartment of Cell and Molecular Biology, John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
    AIDS 31:15-23. 2017
    ..To identify relationships between insulin resistance (IR) and mitochondrial respiration in perinatally HIV-infected youth...
  16. pmc Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy
    Allison L Agwu
    From the Division of Pediatric Infectious Diseases, Department of Pediatrics, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland Center for Biostatistics in AIDS Research CBAR, Harvard School of Public Health, Boston, Massachusetts Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland Monogram Biosciences, South San Francisco, California Boston Children s Hospital and Harvard Medical School, Boston, Massachusetts Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland and Section of Infectious Diseases, Department of Pediatrics, Tulane University School of Medicine, New Orleans, Los Angeles
    Pediatr Infect Dis J 35:777-81. 2016
    ..We characterized phenotypic coreceptor usage among PHIV children and youth with VF on antiretroviral treatment to identify predictors of CXCR4 (X4) tropism which preclude R5 antagonist use...
  17. pmc Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV
    Russell B Van Dyke
    Department of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana
    Clin Infect Dis 63:133-7. 2016
    ..Resistance to newer antiretrovirals and to all antiretrovirals in a class was uncommon. The only factor independently associated with future resistance was a higher peak viral load. ..
  18. pmc Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design
    Paige L Williams
    aCenter for Biostatistics in AIDS ResearchbDepartment of Biostatistics, Harvard T H Chan School of Public Health, Boston, MassachusettscEunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MarylanddTulane University School of Medicine, New Orleans, LouisianaeUniversity of Alabama at Birmingham, Departments of Pediatrics and Microbiology, Birmingham, AlabamafDepartment of Epidemiology, Harvard T H Chan School of Public Health, Boston, MassachusettsgChildren s National Medical Center, Washington, DChFrontier Science Technology and Research Foundation FSTRF, Amherst, New YorkiUniversity of Illinois at Chicago, Chicago, Illinois, USA
    AIDS 30:133-44. 2016
    ..To evaluate the safety of in-utero antiretroviral exposure in children born to mothers with HIV, using a trigger-based design...
  19. pmc Bone mineral density in children and adolescents with perinatal HIV infection
    Linda A DiMeglio
    Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
    AIDS 27:211-20. 2013
    ..To estimate prevalence of low bone mineral density (BMD) in perinatally HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) children, and to determine predictors of BMD in HIV+...
  20. ncbi request reprint Balance and gait abnormalities of a child with West Nile virus infection
    Troy D Moon
    Department of Pediatric Infectious Diseases, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Pediatr Infect Dis J 24:568-70. 2005
    ..West Nile virus-specific IgM and IgG antibodies were detected in the patient's cerebrospinal fluid...
  21. pmc The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs
    Russell B Van Dyke
    Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA
    Front Immunol 7:199. 2016
    ..However, several findings of concern warrant further evaluation, and new ARVs used in pregnancy need to be evaluated. ..
  22. pmc Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission
    Scott C Olson
    aUniversity of Washington bSeattle Children s Research Institute, Seattle, Washington, USA cInstitut de Recherche pour le Développement IRD UMI 174 PHPT, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand dHarvard School of Public Health, Boston, Massachusetts eTulane University School of Medicine, New Orleans, Louisiana, USA
    AIDS 29:1467-71. 2015
    ....
  23. pmc Elevated aspartate aminotransferase-to-platelet ratio index in perinatally HIV-infected children in the United States
    George K Siberry
    From the Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD Department of Epidemiology and Center for Biostatistics in AIDS Research CBAR, Harvard School of Public Health, Boston, MA Department of Pediatrics, Federal University of Minas Gerais, Belo Horizonte, Brazil Children s Diagnostic and Treatment Center, Inc, Fort Lauderdale Department of Pediatrics, University of Florida, Jacksonville Department of Pediatrics, Division of Pediatric Clinical Research, Miller School of Medicine at the University of Miami, Miami, FL and Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA
    Pediatr Infect Dis J 33:855-7. 2014
    ..2-2.2%) and >0.5 in 6.5% (95% CI, 4.3-9.4%); incidence on study was 0.5 (95% CI, 0.2-1.2) and 6.4 (95% CI, 4.8-8.3) per 100 person-years, respectively. Long-term liver outcomes after perinatal HIV infection warrant further study. ..
  24. pmc Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants
    Patricia A Sirois
    Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112, USA
    Pediatr Infect Dis J 32:648-55. 2013
    ..This study evaluated effects of perinatal exposure to antiretroviral (ARV) medications on neurodevelopment of HIV-exposed, uninfected infants...
  25. pmc Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old
    Myron J Levin
    Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO, USA
    J Acquir Immune Defic Syndr 55:197-204. 2010
    ..Quadrivalent human papillomavirus vaccine (QHPV) is > 95% effective in preventing infection with vaccine-type human papillomavirus. The safety and immunogenicity of QHPV are unknown in HIV-infected children...
  26. pmc Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era
    Sharon A Nachman
    Department of Pediatrics, Stony Brook University Medical Center, Stony Brook, NY 11794 8111, USA
    Arch Pediatr Adolesc Med 163:164-71. 2009
    ....
  27. pmc Oral Human Papillomavirus in Youth From the Pediatric HIV/AIDS Cohort Study
    Anna Barbara Moscicki
    From the Department of Pediatrics, Division of Adolescent Medicine, Department of Pediatrics, School of Medicine, University of California, San Francisco, San Francisco, CA Center for Biostatistics in AIDS Research CBAR, Harvard T H Chan School of Public Health, Boston, MA Department of Orofacial Sciences, School of Dentistry, University of California, San Francisco, San Francisco, CA School of Medicine, Tulane University, New Orleans, LA and Maternal and Pediatric Infectious Disease Branch at the Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD, National Institutes of Health NIH, Bethesda, MD
    Sex Transm Dis 43:498-500. 2016
    ..This rate was similar in HIV-exposed but uninfected youth. No association was found with sexual activity; however, low CD4 counts were associated with oral HPV. ..
  28. pmc Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth
    Bill G Kapogiannis
    aMaternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland bCenter for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, Massachusetts cTulane University Health Sciences Center, New Orleans, Louisiana dNew York University, New York, New York eSt Jude Children s Research Hospital, Memphis, Tennessee, USA
    AIDS 30:889-98. 2016
    ..To longitudinally characterize noninvasive markers of liver disease in HIV-infected youth...
  29. ncbi request reprint Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies
    Heather B Jaspan
    Interdisciplinary Program in Molecular and Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    J Clin Virol 31:190-7. 2004
    ..Natural protective mechanisms involving lentivirus-specific antibodies may therefore exist to limit in utero transmission of lentiviruses...
  30. ncbi request reprint Incidence of opportunistic and other infections in HIV-infected children in the HAART era
    Philimon Gona
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Mass, USA
    JAMA 296:292-300. 2006
    ....
  31. doi request reprint Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study
    Kunjal Patel
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Infect Dis 46:507-15. 2008
    ..Given that HIV infection is chronic and that exposure to HAART is likely to be life-long, there is a need to evaluate the long-term effect of HAART on survival in this population...
  32. ncbi request reprint Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol
    Susan Schuval
    Schneider Children s Hospital, Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA
    Arch Pediatr Adolesc Med 158:1007-13. 2004
    ..To evaluate the prevalence of hepatitis C virus (HCV) infection in children with perinatal human immunodeficiency virus (HIV) infection...

Research Grants2

  1. TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT
    Russell Van Dyke; Fiscal Year: 2006
    ..Finally, we will continue to provide leadership in the areas of perinatal transmission of HIV, the complications of HIV infection, adolescent medicine, and behavioral issues such as adherence to therapy. ..
  2. Tulane/LSU HIV/AIDS Clinical Trials Networks Unit
    Russell Van Dyke; Fiscal Year: 2007
    ..unreadable] [unreadable] ADMINISTRATIVE COMPONENT: [unreadable] [unreadable] [unreadable]..